Peptide-Based Gastrointestinal Disorders Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026 Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptidebased gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders such as short bowel syndrome, chronic constipation, and irritable bowel syndrome. In the recent past, some peptide-based therapeutics such as Trulance, Linaclotide, and Teduglutide received approval for the treatment of GIT disorders. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2028 Trulance is a guanylate cyclase-C agonist indicated for the treatment of chronic idiopathic constipation in adults. Linaclotide is a 14 amino acid peptide that acts as an agonist of guanylate cyclase C receptors in the intestine. It is a minimally absorbed agonist of guanylate cyclase C receptors in the intestine and is used for the treatment of chronic constipation and irritable bowel syndrome. Teduglutide is a new recombinant analogue for glucagon-like peptide (GLP) -2, a natural occurring peptide, which is secreted primarily by the lower gastrointestinal tract. Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics Frequent approval and launch of novel peptide-based gastrointestinal disorders therapeutics in key regions is expected to drive the global peptide-based gastrointestinal disorders therapeutics market growth over the forecast period. For instance, in 2017, Synergy Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its new drug TRULANCE (plecanatide) 3 mg tablet. This drug is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. In 2012, Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. received the U.S. Food and Drug Administration approval for its drug called Linzess (linaclotide). Linzess (linaclotide) is a guanylate cyclase-C agonist used for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). In 2016, Ironwood Pharmaceuticals, Inc.’s partner, Astellas Pharma Inc., received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for Linzess (linaclotide), and in 2017, Astellas Pharma Inc. launched Linzess (linaclotide) in Japan. In 2012, NPS Pharmaceuticals, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its drug Gattex (Teduglutide (rDNA origin)). Gattex 0.05 mg/kg/d injection is a new, recombinant analog of human glucagon-like peptide 2, a protein involved in the rehabilitation of the intestinal lining. It is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Sucg frequent approval is expected to cather peptide-based gastrointestinal disorders therapeutics market growth in near future. Report includes chapters which deeply display the following deliverable about industry : • Peptide-Based Gastrointestinal Disorders Therapeutics Market Research Objective and Assumption • Peptide-Based Gastrointestinal Disorders Therapeutics Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Peptide-Based Gastrointestinal Disorders Therapeutics Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Peptide-Based Gastrointestinal Disorders Therapeutics Market, By Regions • Peptide-Based Gastrointestinal Disorders Therapeutics Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Peptide-Based Gastrointestinal Disorders Therapeutics Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Peptide-Based Gastrointestinal Disorders Therapeutics Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Peptide-Based Gastrointestinal Disorders Therapeutics Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Peptide-Based Gastrointestinal Disorders Therapeutics Market Regional Analysis North America peptide-based gastrointestinal disorders therapeutics market is expected to exhibit good growth over the forecast period, owing to presence of major players and adoption of strategies such as mergers and collaborations by them for novel peptide-based therapeutics. For instance, in February 2018, Cipher Pharmaceuticals Inc. acquired exclusive Canadian rights of the U.S. Food and Drug Administration approved drug Trulance (plecanatide) from Synergy Pharmaceuticals Inc. After the acquisition, Cipher Pharmaceuticals Inc. will develop, market, distribute, and sell Trulance (plecanatide) in the Canadian Market. Browse Report For More Information @ https://www.coherentmarketinsights.com/ongoinginsight/peptide-based-gastrointestinal-disorders-therapeutics-market-2028 Asia Pacific peptide-based gastrointestinal disorders therapeutics market is expected to exhibit significant growth over the forecast period, owing to increasing investments made by players in the region to receive approval of novel peptide-based therapeutics. For instance, in 2014, Ironwood Pharmaceuticals, Inc. received US$ 15 million from Astellas Pharma Inc., a Japanbased pharmaceutical company, for initiating Phase III clinical trial of Linzess (linaclotide) in Japan, and receive its approval from Japanese Ministry of Health, Labor, and Welfare in 2016. Ironwood Pharmaceuticals, Inc. and Astellas Pharma Inc. were under strategic partnership since 2009 for developing and commercializing linaclotide in Japan. Peptide-Based Gastrointestinal Disorders Therapeutics Market Key Players Key players operating in the global peptide-based gastrointestinal disorders therapeutics market include Ironwood Pharmaceuticals, Inc., NPS Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Astellas Pharma Inc., Allergan plc., and Cipher Pharmaceuticals Inc. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Peptide-based gastrointestinal (GIT) disorders therapeutics are drugs that are used for the treatment of various GIT disorders.
© Copyright 2024 Paperzz
